Join to View Full Profile
12902 Usf Magnolia DrTampa, FL 33612
Phone+1 813-974-0706
Fax+1 813-974-4325
Dr. Beaupre is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 1999 - 2003- University of Miami/Jackson Health SystemResidency, Internal Medicine, 1997 - 1999
McGovern Medical School at UTHealthClass of 1997
Certifications & Licensure
FL State Medical License 1998 - 2027
Clinical Trials
- Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2005 Aug 01
- Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Start of enrollment: 2011 Feb 01
- Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2011 May 01
Publications & Presentations
PubMed
- 35 citationsModulation of RNA splicing enhances response to BCL2 inhibition in leukemia.Eric Wang, Jose Mario Bello Pineda, Won Jun Kim, Sisi Chen, Jessie Bourcier
Cancer Cell. 2023-01-09 - 9 citationsNavigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion RecommendationsElly Barry, Jaimie A Walsh, Scott L. Weinrich, Darrin M. Beaupre, Eileen R. Blasi
Paediatric Drugs. 2021-06-26 - 7 citationsPhase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.Wyndham H. Wilson, Tycel Phillips, Leslie Popplewell, Sven de Vos, Saurabh Chhabra
Leukemia & Lymphoma. 2021-04-15
Press Mentions
Oncology Drugs Granted FDA Designations in March 2025April 1st, 2025- IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal MelanomaMarch 31st, 2025
- IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024October 25th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
